Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 2
2012 4
2013 8
2014 4
2015 11
2016 11
2017 26
2018 17
2019 7
2020 4
2021 6
2022 2
2023 3
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Green JB, et al. Among authors: engel ss. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. N Engl J Med. 2015. PMID: 26052984 Free article. Clinical Trial.
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Romero-Gómez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS; MK-6024 P001 Study Group. Romero-Gómez M, et al. Among authors: engel ss. J Hepatol. 2023 Oct;79(4):888-897. doi: 10.1016/j.jhep.2023.05.013. Epub 2023 Jun 22. J Hepatol. 2023. PMID: 37355043 Free article. Clinical Trial.
Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD.
Akbari C, Dodd M, Stål P, Nasr P, Ekstedt M, Kechagias S, Vessby J, Rorsman F, Zhang X, Wang T, Jemielita T, Fernandes G, Engel SS, Hagström H, Shang Y. Akbari C, et al. Among authors: engel ss. JHEP Rep. 2023 Sep 25;6(2):100915. doi: 10.1016/j.jhepr.2023.100915. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38293684 Free PMC article.
Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease.
Shang Y, Akbari C, Dodd M, Zhang X, Wang T, Jemielita T, Fernandes G, Engel SS, Nasr P, Vessby J, Rorsman F, Kechagias S, Stål P, Ekstedt M, Hagström H. Shang Y, et al. Among authors: engel ss. Hepatology. 2024 Aug 7. doi: 10.1097/HEP.0000000000001045. Online ahead of print. Hepatology. 2024. PMID: 39110990
Glucagon receptor antagonism induces increased cholesterol absorption.
Guan HP, Yang X, Lu K, Wang SP, Castro-Perez JM, Previs S, Wright M, Shah V, Herath K, Xie D, Szeto D, Forrest G, Xiao JC, Palyha O, Sun LP, Andryuk PJ, Engel SS, Xiong Y, Lin S, Kelley DE, Erion MD, Davis HR, Wang L. Guan HP, et al. Among authors: engel ss. J Lipid Res. 2015 Nov;56(11):2183-95. doi: 10.1194/jlr.M060897. Epub 2015 Sep 15. J Lipid Res. 2015. PMID: 26373568 Free PMC article.
Progression of glucose-lowering diabetes therapy in TECOS.
Bethel MA, Engel SS, Stevens SR, Lokhnygina Y, Ding J, Josse RG, Alvarsson M, Hramiak I, Green JB, Peterson ED, Holman RR; TECOS Study Group. Bethel MA, et al. Among authors: engel ss. Endocrinol Diabetes Metab. 2018 Dec 22;2(1):e00053. doi: 10.1002/edm2.53. eCollection 2019 Jan. Endocrinol Diabetes Metab. 2018. PMID: 30815579 Free PMC article.
Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.
Abdurrachim D, Lek S, Lin Ong CZ, Wong CK, Zhou Y, Wee A, Soon G, Kendall TJ, Idowu MO, Hendra C, Saigal A, Krishnan R, Chng E, Tai D, Ho G, Forest T, Raji A, Talukdar S, Chin CL, Baumgartner R, Engel SS, Bakar Ali AA, Kleiner DE, Sanyal AJ. Abdurrachim D, et al. Among authors: engel ss. J Hepatol. 2024 Nov 27:S0168-8278(24)02734-X. doi: 10.1016/j.jhep.2024.11.032. Online ahead of print. J Hepatol. 2024. PMID: 39612947
Pancreatic Safety of Sitagliptin in the TECOS Study.
Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR; TECOS Study Group. Buse JB, et al. Among authors: engel ss. Diabetes Care. 2017 Feb;40(2):164-170. doi: 10.2337/dc15-2780. Epub 2016 Sep 14. Diabetes Care. 2017. PMID: 27630212 Free PMC article. Clinical Trial.
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.
Jalaludin MY, Deeb A, Zeitler P, Garcia R, Newfield RS, Samoilova Y, Rosario CA, Shehadeh N, Saha CK, Zhang Y, Zilli M, Scherer LW, Lam RLH, Golm GT, Engel SS, Kaufman KD, Shankar RR. Jalaludin MY, et al. Among authors: engel ss. Pediatr Diabetes. 2022 Mar;23(2):183-193. doi: 10.1111/pedi.13282. Epub 2021 Dec 20. Pediatr Diabetes. 2022. PMID: 34779103
95 results